Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Ms. Amy Trombly is the Chief Executive Officer of Sonoma Pharmaceuticals Inc, joining the firm since 2019.
What is the price performance of SNOA stock?
The current price of SNOA is $1.3, it has decreased 0.14% in the last trading day.
What are the primary business themes or industries for Sonoma Pharmaceuticals Inc?
Sonoma Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Sonoma Pharmaceuticals Inc market cap?
Sonoma Pharmaceuticals Inc's current market cap is $6.2M
Is Sonoma Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Sonoma Pharmaceuticals Inc, including 3 strong buy, 3 buy, 1 hold, 0 sell, and 3 strong sell